Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer

被引:43
作者
Goffin, JR
Straume, O
Chappuis, PO
Brunet, JS
Bégin, LR
Hamel, N
Wong, N
Akslen, LA
Foulkes, WD
机构
[1] McGill Univ, Dept Med, Montreal, PQ, Canada
[2] McGill Univ, Sir Mortimer B Davis Jewish Hosp, Canc Prevent Ctr, Montreal, PQ H2W 1S6, Canada
[3] McGill Univ, Dept Pathol, Montreal, PQ, Canada
[4] McGill Univ, Dept Surg, Montreal, PQ H3A 2T5, Canada
[5] Algorithme Pharma, Montreal, PQ H7V 4B4, Canada
[6] McGill Univ, Program Canc Genet, Montreal, PQ H2W 1S6, Canada
[7] McGill Univ, Res Inst, Mcgill Univ Hlth Ctr, Montreal, PQ H2W 1S6, Canada
[8] McGill Univ, Dept Human Genet, Montreal, PQ, Canada
[9] Haukeland Univ Hosp, Gade Inst, Dept Pathol, N-5021 Bergen, Norway
[10] Tufts Univ, Dept Med, Tufts New England Med Ctr, Div Hematol Oncol, Boston, MA 02111 USA
关键词
hereditary breast cancer; angiogenesis; factor VIII; chemotheraphy; survival;
D O I
10.1038/sj.bjc.6601195
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Glomeruloid microvascular proliferation (GMP) in breast cancer independently adversely affected survival ( relative risk 1.9, 95% CI: 1.2 - 3.0), particularly among women who received adjuvant chemotherapy ( 10-year survival 27 vs 69%, P = 0.0003), and was significantly associated with p53 overexpression and BRCA1 germline mutations. The presence of GMP may influence treatment decisions.
引用
收藏
页码:1031 / 1034
页数:4
相关论文
共 23 条
[1]   BRCA1 and BRCA2:: From molecular genetics to clinical medicine [J].
Blackwood, MA ;
Weber, BL .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (05) :1969-1977
[2]   A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer [J].
Chapppuis, PO ;
Goffin, J ;
Wong, N ;
Perret, C ;
Ghadirian, P ;
Tonin, PN ;
Foulkes, WD .
JOURNAL OF MEDICAL GENETICS, 2002, 39 (08) :608-610
[3]   CONTROL OF ANGIOGENESIS IN FIBROBLASTS BY P53 REGULATION OF THROMBOSPONDIN-1 [J].
DAMERON, KM ;
VOLPERT, OV ;
TAINSKY, MA ;
BOUCK, N .
SCIENCE, 1994, 265 (5178) :1582-1584
[4]  
de Jong JS, 2000, HISTOPATHOLOGY, V36, P306
[5]   Vascular endothelial growth factor and prognosis in patients with node-negative breast cancer [J].
De Paola, F ;
Granato, AM ;
Scarpi, E ;
Monti, F ;
Medri, L ;
Bianchi, S ;
Amadori, D ;
Volpi, A .
INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (02) :228-233
[6]   The p53 tumor suppressor: Critical regulator of life & death in cancer [J].
Fisher, DE .
APOPTOSIS, 2001, 6 (1-2) :7-15
[7]  
Foulkes WD, 1997, CLIN CANCER RES, V3, P2465
[8]   Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma -: 10-year follow-up data [J].
Goffin, JR ;
Chappuis, PO ;
Bégin, LR ;
Wong, N ;
Brunet, JS ;
Hamel, N ;
Paradis, AJ ;
Boyd, J ;
Foulkes, WD .
CANCER, 2003, 97 (03) :527-536
[9]  
Greenblatt MS, 2001, CANCER RES, V61, P4092
[10]   BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair [J].
Hartman, AR ;
Ford, JM .
NATURE GENETICS, 2002, 32 (01) :180-184